SCHEMBL216014

SCHEMBL216014

COc1ccc(COc2ccc3c(N)n[nH]c3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.54
CNR1 P21554 1/20 0.54
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MAOB P27338 1/20 0.48
MAP2K4 P45985 1/20 0.47
IKBKE Q14164 1/20 0.46
APP P05067 5/20 0.45
PDPK1 O15530 3/20 0.45
MEN1 O00255 1/20 0.45
CASP3 P42574 1/20 0.45
KMT2A Q03164 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
AURKA O14965 1/20 0.43
TGFBR1 P36897 1/20 0.43
ROCK1 Q13464 1/20 0.43
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214502 0.89 CNR2 (0.58) CNR2CNR1NPC1RAB9AMAOB
SCHEMBL18640073 0.89 IKBKE (0.43) CNR2CNR1IKBKEPDPK1JAK2
SCHEMBL18639944 0.89 MAOB (0.47) CNR2CNR1NPC1RAB9AMAOB
SCHEMBL13737545 0.89 KIT (0.52) CNR2CNR1MAP2K4APPPDPK1
SCHEMBL18639891 0.87 MAOB (0.56) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL18639995 0.87 NTRK1 (0.43) CNR2CNR1MAOBPDPK1TDP1
SCHEMBL18639883 0.86 MAOB (0.49) MAOBAPPPDPK1JAK2
SCHEMBL18639940 0.86 PDPK1 (0.44) CNR2CNR1MAOBMAP2K4IKBKE
SCHEMBL11963403 0.86 IKBKE (0.54) RAB9AMAOBIKBKEJAK2
SCHEMBL18639882 0.85 MAOA (0.50) CNR2CNR1MAOBIKBKEPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017045751-A1 COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 WO disclosed
WO-2017045751-A1 COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 WO disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK CNR2 1520/4885CNR1 1038/4885NPC1 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.